ClinicalTrials.gg
RecruitingNCT04093986HELPFULUpdated Jun 18, 2026

Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation

An observational study in Sickle Cell Disease and Sickle Cell Anemia, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Children's Hospital Medical Center, Cincinnati · Observational

How we know

From the registry’s dates

  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 11 under way, none of them phase 3. Anemia, Sickle Cell · Children's Hospital Medical Center, Cincinnati.

Started
2019
the only one that year
Observational
9 of 30
4 open now
Primary completion
2028-12
later than 7 of 10 live
Registered
20th of 30
by date

Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, this one is the only one that started in 2019, is one of 9 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 20th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

7 of the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati are open now, in 6 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.

Read the detailed description

Hydroxyurea (hydroxycarbamide) is the primary disease-modifying therapy for individuals with sickle cell disease (SCD) and is both US FDA- and EMA-approved for SCD treatment. Decades of research have documented that hydroxyurea reduces morbidity and mortality for affected patients. Although its primary mechanism of action for SCD is the induction of fetal hemoglobin (HbF) that prevents erythrocyte sickling, hydroxyurea is also a ribonucleotide reductase inhibitor with dose-dependent cytotoxic effects. Based on laboratory data, hydroxyurea is considered to be a potential human mutagen, clastogen, teratogen, and even carcinogen. However, most of these are theoretical human risks; for example, teratogenic effects of hydroxyurea are based on in vitro cellular data and supra-pharmacological dosing of animals, with no documented abnormalities in humans. Despite the lack of in vivo human data, the package insert for hydroxyurea, sold as either Hydrea® or Droxia® (Bristol-Myers Squibb), or as Siklos® (Addmedica) lists both pregnancy and lactation as contraindications for treatment.

This contraindication label is critically important, since women with SCD frequently have high-risk pregnancies throughout gestation, with increased morbidity and mortality for both the mother and baby. Acute clinical complications for the mother occur commonly during gestation, while placental insufficiency through repeated infarctions also leads to increased fetal morbidity. Protection of the mother's health during pregnancy is therefore a high priority, which historically has been aided by judicious use of transfusions and management by a multidisciplinary healthcare team. In the current era, many women with SCD of child-bearing age are taking daily oral hydroxyurea with an excellent treatment effect, so its forced discontinuation around the time of pregnancy represents cessation of effective therapy. Abrupt withdrawal of hydroxyurea is typically deleterious and may not be justified in this setting. Numerous published case reports and small series have described the safe use of hydroxyurea as anti-neoplastic therapy during pregnancy in women with cancer; moreover, anecdotal experience of >100 pregnancies with hydroxyurea exposure did not document any teratogenicity.

Based on the importance of determining the actual risks and benefits of continuing hydroxyurea as disease-modifying therapy during pregnancy to protect both mothers and babies, and the lack of documented in vivo data, the safety of hydroxyurea during gestation and subsequent lactation was recently identified as an important knowledge gap by the NHLBI evidence-based SCD guidelines. Further data collection is needed regarding the actual effects of hydroxyurea for women with SCD during both pregnancy and while breastfeeding. Accordingly, we will conduct a multinational research project to retrospectively capture known human exposures to hydroxyurea in the setting of SCD, which have occurred during gestation and/or lactation, to elucidate the outcomes for the mothers and their babies. Those outcomes will be compared to pregnancies in these same women without hydroxyurea exposure.

03

Conditions studied

  • Sickle Cell Disease
  • Sickle Cell Anemia

Browse trials for

Keywords

  • Hydroxyurea
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Clinical and laboratory data on up to 200 women with SCD with hydroxyurea exposure during either gestation or lactation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical records or data available from previous clinical care prior to June 20, 2019 of pregnant females with SCD, including women who miscarried, had a still birth, or completed labor at any gestational stage, with any hydroxyurea exposure during either pregnancy and/or while breastfeeding.
  • Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.

Exclusion criteria

Exclusion Criteria:

  • Unavailable medical records or lack of information about hydroxyurea exposure.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective Chart Review

    Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.

    Other: Chart Review

  • Participant Survey and Retrospective Chart Review

    Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.

    Other: Chart Review · Other: Survey

Interventions

  • OtherChart Review

    Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.

  • OtherSurvey

    Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.

06

What researchers measure

Primary outcomes

  1. How long pregnant women with Sickle Cell Disease (SCD) were exposed to Hydroxyurea.

    Obtain data on length of time women with SCD were exposed to Hydroxyurea prior to pregnancy, during pregnancy, and after pregnancy.

    Time frame: Through completion of pregnancy, an average of 2 years

  2. Dose of hydroxyurea taken during pregnancy.

    Obtain data on the dose of Hydroxyurea taken prior to conception, during and after pregnancy.

    Time frame: Through completion of pregnancy, an average of 2 years

  3. How long infants were exposed to Hydroxyurea.

    Obtain data on length of time infants were exposed to Hydroxyurea during gestation and while breastfeeding.

    Time frame: Through study completion, an average of 2 years

  4. Dose of hydroxyurea exposure in infants.

    Obtain data on the dose of Hydroxyurea taken by mother during gestation and while breastfeeding infant.

    Time frame: Through study completion, an average of 2 years

  5. Health outcomes of infants exposed to Hydroxyurea.

    Obtain data on the health of infant after exposure to Hydroxyurea during gestation and while breastfeeding including any complications of mother's pregnancy or delivery as well as any congenital malformations or medical conditions in infancy.

    Time frame: Through study completion, an average of 2 years

  6. Pregnancy in Sickle Cell Disease (SCD).

    Compare pregnancy and delivery complications in women with SCD exposed to Hydroxyurea to pregnancy and delivery complications in women with SCD without Hydroxyurea exposure.

    Time frame: Start of pregnancy until June 2019

  7. Comparative analysis of congenital malformations or medical conditions in infants

    Compare the rate of congenital malformations and/or medical conditions in infants exposed to hydroxyurea during gestation and breastfeeding to the rate of these events in infants without hydroxyurea exposure, with data collected descriptively by self-report or chart review as applicable.

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2019 (actual). Primary completion is estimated for Dec 2028, 108 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2019
First posted
Sep 18, 2019
StartActual
Dec 22, 2019
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04093986
Responsible party
Sponsor
First posted
Sep 18, 2019
Start date
Dec 22, 2019
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jun 18, 2026

Study contacts

Teresa Latham
Contact
Teresa.Latham@cchmc.org
513-803-7922
Russell Ware, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion